Home Medicine High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy
Article
Licensed
Unlicensed Requires Authentication

High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy

  • Aldo Clerico EMAIL logo , Daniela Maria Cardinale , Martina Zaninotto , Nadia Aspromonte , Maria Teresa Sandri , Claudio Passino , Marco Migliardi , Marco Perrone , Antonio Fortunato , Andrea Padoan ORCID logo , Tommaso Trenti , Sergio Bernardini , Laura Sciacovelli ORCID logo , Furio Colivicchi , Domenico Gabrielli and Mario Plebani ORCID logo
Published/Copyright: May 22, 2020
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 59 Issue 3

Abstract

Important advances achieved in pharmacological cancer treatment have led progressively to a reduction in mortality from many forms of cancer, and increasing numbers of previously incurable patients can now hope to become cancer-free. Yet, to achieve these improved outcomes a high price has been paid in terms of untoward side effects associated with treatment, cardio-toxicity in particular. Several recent studies have reported that cardiac troponin assay using high-sensitivity methods (hs-cTn) can enable the early detection of myocardial injury related to chemotherapy or abuse of drugs that are potentially cardiotoxic. Several authors have recently suggested that changes in hs-cTn values enable the early diagnosis of cardiac injury from chemotherapy, thus potentially benefitting cancer patients with increased troponin values by initiating early cardioprotective therapy. However, large randomised clinical trials are needed in order to evaluate the cost/benefit ratio of standardised protocols for the early detection of cardiotoxicity using the hs-cTn assay in patients treated with chemotherapy.

Keywords: cardiac troponin; cardio-toxicity; chemotherapy; high-sensitivity methods; myocardial injury
Corresponding author: Aldo Clerico, MD, Laboratory of Cardiovascular Endocrinology and Cell Biology, Department of Laboratory Medicine, Scuola Superiore Sant’Anna e Fondazione CNR – Regione Toscana G. Monasterio, Via Trieste 41, 56126 Pisa, Italy

  1. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: Authors state no conflict of interest.

References

1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronarysyndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.10.1093/eurheartj/ehv320Search in Google Scholar PubMed

2. Wu AH, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Lianos J, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2018;64:645–55.10.1373/clinchem.2017.277186Search in Google Scholar PubMed

3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol 2018;72:2231–64.10.1093/eurheartj/ehy655Search in Google Scholar PubMed

4. Clerico A, Fortunato A, Ripoli A, Prontera C, Zucchelli GC, Emdin M. Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008;46:804–8.10.1515/CCLM.2008.162Search in Google Scholar PubMed

5. Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial tissue renewal? Clin Chem Lab Med 2009;47:1167–77.10.1515/CCLM.2009.320Search in Google Scholar PubMed

6. Prontera C, Fortunato A, Storti S, Mercuri A, Longombardo G, Zucchelli GC, et al. Evaluation of analytical performance of the siemens ADVIA TnI ultra immunoassay. Clin Chem 2007;53:1722–3.10.1373/clinchem.2007.089995Search in Google Scholar PubMed

7. Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, et al. Multicentre analytical evaluation of a high-sensitive troponin T assay. Clin Chim Acta 2011;412:748–54.10.1016/j.cca.2010.12.034Search in Google Scholar PubMed

8. Venge P, James S, Jansson L, Lindahl B. Clinical performance of two highly sensitive cardiac troponin I assays. Clin Chem 2009;55:109–16.10.1373/clinchem.2008.106500Search in Google Scholar PubMed

9. Krintus M, Kozinsk M, Boudry P, Capell NE, Köller U, Lackner K, et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin Chem Lab Med 2016;52:1657–65.10.1515/cclm-2014-0107Search in Google Scholar PubMed

10. Caselli C, Cangemi G, Masotti S, Ragusa R, Gennai I, Del Ry S, et al. Plasma cardiac troponin I concentrations in healthy neonates, children and adolescents measured with a high sensitive immunoassay method: high sensitive troponin I in pediatric age. Clin Chim Acta 2016;458:68–71.10.1016/j.cca.2016.04.029Search in Google Scholar PubMed

11. Masotti S, Prontera C, Musetti V, Storti S, Ndreu R, Zucchelli GC, et al. Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I. Clin Chem Lab Med 2018;56:492–501.10.1515/cclm-2017-0387Search in Google Scholar PubMed

12. Masotti S, Musetti V, Prontera C, Storti S, Passino C, Zucchelli G, et al. Evaluation of analytical performance of a chemiluminescence enzyme immunoassay (CLEIA) for cTnI using the automated AIA-CL2400 platform. Clin Chem Lab Med 2018;56:e174–6.10.1515/cclm-2017-1101Search in Google Scholar PubMed

13. Musetti V, Masotti S, Prontera C, Storti S, Ndreu N, Zucchelli GC, et al. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I. Clin Chem Lab Med 2018;56:e229–31.10.1515/cclm-2018-0054Search in Google Scholar PubMed

14. Clerico A, Zaninotto M, Padoan A, Masotti S, Musetti V, Prontera C, et al. Evaluation of analytical performance of immunoassay methods for cardiac troponin I and T: from theory to practice. Adv Clin Chem 2019;93:239–62.10.1016/bs.acc.2019.07.005Search in Google Scholar PubMed

15. Clerico A, Lippi G. The state-of-the-art of “high-sensitivity” immunoassay for measuring cardiac troponin I and T. J Lab Precis Med 2018;3:53.10.21037/jlpm.2018.05.04Search in Google Scholar

16. Clerico A, Ripoli A, Zaninotto M, Masotti S, Musetti V, Ciaccio M, et al. Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy volunteers and patients admitted to emergency department with acute coronary syndrome: a multi-center study. Clin Chim Acta 2019;496:25–34.10.1016/j.cca.2019.06.012Search in Google Scholar PubMed

17. Clerico A, Zaninotto M, Ripoli A, Masotti S, Prontera C, Passino C, et al. The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology, and clinical implications. Clin Chem Lab Med 2017;55:1634–51.10.1515/cclm-2016-0933Search in Google Scholar PubMed

18. Marjot J, Kaier TE, Martin ED, Reji SS, Copeland O, Iqbal M, et al. Quantifying the release of biomarkers of myocardial necrosis from cardiac myocytes and intact myocardium. Clin Chem 2017;63:990–6.10.1373/clinchem.2016.264648Search in Google Scholar PubMed PubMed Central

19. Mair J, Lindahl B, Hammarsten O, Müller C, Giannitsis E, Huber K, et al. How is cardiac troponin released from injured myocardium? Eur Heart J Acute Cardiovasc Care 2018;7:553–60.10.1177/2048872617748553Search in Google Scholar PubMed

20. Ndreu R, Musetti V, Masotti S, Zaninotto M, Prontera C, Zucchelli GC, et al. Evaluation of the cTnT immunoassay using quality control samples. Clin Chim Acta 2019;495:269–70.10.1016/j.cca.2019.04.068Search in Google Scholar PubMed

21. Musetti V, Masotti S, Prontera C, Ndreu R, Zucchelli G, Passino C, et al. Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples. Clin Chem Lab Med 2019;57:e241–3.10.1515/cclm-2019-0032Search in Google Scholar PubMed

22. Bergmann O, Zdunek S, Felker A, Salhpoor M, Alkass K, Bernard S, et al. Dynamics of cell generation and turnover in the human heart. Cell 2015;161:1566–75.10.1016/j.cell.2015.05.026Search in Google Scholar PubMed

23. Sze J, Mooney J, Barzi F, Hillis GS, Chow CK. Cardiac troponin and its relationship to cardiovascular outcomes in community populations. A systematic review and meta-analysis. Heart Lung Circ 2016;25:217–28.10.1016/j.hlc.2015.09.001Search in Google Scholar PubMed

24. van der Linden N, Klinkenberg LJ, Bekers O, Loon L, Dieijen-Visser MP, Zeegers MP, et al. Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine 2016;95:e5703.10.1097/MD.0000000000005703Search in Google Scholar PubMed PubMed Central

25. Hughes MF, Ojeda F, Saarela O, Jørgensen T, Zeller T, Palosaari T, et al. Association of repeatedly measured high-sensitivity-assayed troponin I with cardiovascular disease events in a general population from the MORGAM/BiomarCaRE Study. Clin Chem 2017;63:334–42.10.1373/clinchem.2016.261172Search in Google Scholar PubMed

26. Zellweger MJ, Haaf P, Maraun M, Osterhues HH, Keller U, Müller-Brand J, et al. Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus. Int J Cardiol 2017;244:37–42.10.1016/j.ijcard.2017.05.069Search in Google Scholar PubMed

27. Sigurdardottir FD, Lynbakken MN, Holmen OL, Dalen H, Hveem K, Røsjø H, et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the North-Trøndelag Health [HUNT] Study). Am J Cardiol 2018;121:949–55.10.1016/j.amjcard.2018.01.004Search in Google Scholar PubMed

28. Willeit P, Welsh P, Evans JD, Tschiderer L, Boachie C, Wouter Jukema J, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol 2017;70:558–68.10.1016/j.jacc.2017.05.062Search in Google Scholar PubMed PubMed Central

29. Welsh P, Preiss D, Shah AS, McAllister D, Briggs A, Boachie C, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clin Chem 2018;64:1607–16.10.1373/clinchem.2018.292086Search in Google Scholar PubMed PubMed Central

30. Zhu K, Knuiman M, Divitini M, Murray K, Lim EM, St John A, et al. High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australian population-based cohort. Heart 2018;104:895–903.10.1136/heartjnl-2017-312093Search in Google Scholar PubMed

31. Passino C, Aimo A, Masotti S, Musetti V, Prontera C, Emdin M, et al. Cardiac troponins as biomarkers for cardiac disease. Biomark Med 2019;13:325–30.10.2217/bmm-2019-0039Search in Google Scholar PubMed

32. Aakre KM, Røraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variation in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem 2014;60:838–47.10.1373/clinchem.2013.216978Search in Google Scholar PubMed

33. Corte Z, Garcia C, Venta R. Biological variation of cardiac troponin T in patients with end-stage renal disease and in healthy individuals. Ann Clin Biochem 2015;52:53–60.10.1177/0004563214545116Search in Google Scholar PubMed

34. Fournier S, Iten L, Marques-Vidal P, Boulat O, Bardy D, Beggah A, et al. Circadian rhythm of blood cardiac troponin T concentration. Clin Res Cardiol 2017;106:1026–32.10.1007/s00392-017-1152-8Search in Google Scholar PubMed

35. Meijers WC, Van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 2017;19:3457–65.10.1002/ejhf.669Search in Google Scholar PubMed PubMed Central

36. van der Linden N, Hilderink JM, Cornelis T, Kimenai DM, Kinkenberg LJ, van Doom WP, et al. Twenty-four-hour biological variation profiles of cardiac troponin I in individuals with or without chronic kidney disease. Clin Chem 2017;63:1655–6.10.1373/clinchem.2017.275107Search in Google Scholar PubMed

37. Zaninotto M, Padoan A, Mion MM, Marinova M, Plebani M. Short-term biological variation and diurnal rhythm of cardiac troponin I (Access hs-TnI) in healthy subjects. Clin Chim Acta 2020;504:163–7.10.1016/j.cca.2020.02.004Search in Google Scholar PubMed

38. Clerico A, Ripoli A, Masotti S, Musetti V, Aloe R, Dipalo M, et al. Evaluation of 99th percentile and reference change values of a high-sensitivity cTnI method: a multicenter study. Clin Chim Acta 2019;493:156–61.10.1016/j.cca.2019.02.029Search in Google Scholar PubMed

39. Clerico A, Masotti S, Musetti V, Ripoli A, Aloe R, Di Pietro M, et al. Evaluation of 99th percentile and reference change values of the hs-cTnI method using ADVIA Centaur XTP platform: a multicenter study. Clin Chim Acta 2019;495:161–6.10.1016/j.cca.2019.04.056Search in Google Scholar PubMed

40. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcome of anticancer therapy-indiced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020. pii: ehaa006. doi: 10.1093/eurheartj/ehaa006 [Epub ahead of print].10.1093/eurheartj/ehaa006Search in Google Scholar PubMed

41. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh E. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017;70:2536–51.10.1016/j.jacc.2017.09.1096Search in Google Scholar PubMed PubMed Central

42. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh E. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 2017;70:2552–65.10.1016/j.jacc.2017.09.1095Search in Google Scholar PubMed PubMed Central

43. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–20.10.1016/j.jacc.2009.03.095Search in Google Scholar PubMed

44. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Civelli M, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;133:1981–8.10.1161/CIRCULATIONAHA.114.013777Search in Google Scholar PubMed

45. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37:2768–801.10.1093/eurheartj/ehw211Search in Google Scholar PubMed

46. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063–93.10.1093/ehjci/jeu192Search in Google Scholar PubMed PubMed Central

47. López-Fernández T, Martín Garcıa A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, et al. Cardio-oncohematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol 2017;70:474–86.10.1016/j.recesp.2016.12.021Search in Google Scholar

48. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncology 2017;35:893–911.10.1200/JCO.2016.70.5400Search in Google Scholar PubMed

49. Chukwu EO, Barasch E, Mihalatos DG, Katz A, Lachmann J, Han J, et al. Relative importance of errors in left ventricular quantitation by two-dimensional echocardiogaphy: insights from three-dimensional echocardiography and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2008;21:990–7.10.1016/j.echo.2008.07.009Search in Google Scholar PubMed

50. Wood PW, Choy JB, Nanda NC, Becher H. Left ventricular ejection fraction and volumes: it depends on the imaging method. Echocardiogtaphy 2014;31:87–100.10.1111/echo.12331Search in Google Scholar PubMed PubMed Central

51. Suwatanaviroj T, He W, Pituskin E, Paterson I, Choy J, Becher H. What is the minimum change in left ventricular ejection fraction, which can be measured with contrast echocardiography? Echo Res Pract 2018;5:71–7.10.1530/ERP-18-0003Search in Google Scholar PubMed PubMed Central

52. Suwatanaviroj T, He W, Mirhadi E, Paakanen R, Pituskin E, Paterson I, et al. Variability of left ventricular volume and ejection fraction measurements using contrast echocardiography: the influence of the left ventricular length measurements in a large cohort of patients during monitoring cardiotoxic effects of chemotherapy. Echocardiography 2018;35:322–8.10.1111/echo.13783Search in Google Scholar PubMed

53. Gori S, Barbieri E, Barni S, Belli L, Ciccarese M, Falci C, et al. Gruppo di lavoro cardio-oncologia 2019 AIOM – AICO – ARCA – ICOS – SIAARTI – SIBioC – SIE. Cardio-Oncologia 2019. Raccomandazioni Pratiche. Brescia, Italia: Intermedia Editore, 2019, pag. 1–84.Search in Google Scholar

54. Valentine CM, Tcheng JE, Waites T. Translating the Translation. What clinicians should know about the fourth universal definition of myocardial infarction. J Am Coll Cardiol 2018;72:2668–70.10.1016/j.jacc.2018.10.015Search in Google Scholar PubMed

55. Thygesen K. What’s new in the fourth universal definition of myocardial infarction? Eur Heart J 2018;38:3757–8.10.1093/eurheartj/ehy655Search in Google Scholar PubMed

56. Zhang S, Uecker M, Voit D, Merboldt KD, Frahm J. Real-time cardiovascular magnetic resonance at high temporal resolution: radial FLASH with nonlinear inverse reconstruction. J Cardiovsc Magn Reson 2010;12:39.10.1186/1532-429X-12-39Search in Google Scholar PubMed PubMed Central

57. Fagiry MA, Mistafa IA, Mahmoud MZ. Two-dimensional echocardiography in the diagnosis of ischemic heart disease. J Rad Res Appl Sci 2019;12:177–85.10.1080/16878507.2019.1594129Search in Google Scholar

58. Plebani M, Sciacovelli L, Bernardi D, Aita A, Antionelli G, Padoan A. What information on measurement uncertainty should be communicated to clinicians, and how? Clin Biochem 2018;57:18–22.10.1016/j.clinbiochem.2018.01.017Search in Google Scholar PubMed

59. Braga L, Vinci B, Leo CG, Picano E. The true cost of cardiovascular imaging: focusing on downstream, indirect, and environmental costs. Cardiovasc Ultrasound 2013;11:10.10.1186/1476-7120-11-10Search in Google Scholar PubMed PubMed Central

60. Malik SB, Chen N, Parker 3rd RA, Hsu JY. Transthoracic echocardiography: pitfalls and limitations as delineated at cardiac CT and MR imaging. Radiographics 2017;37:383–406.10.1148/rg.2017160105Search in Google Scholar PubMed

61. Cardinale D, Sandri MT, Colombo A, Clombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–54.10.1161/01.CIR.0000130926.51766.CCSearch in Google Scholar PubMed

62. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by Angiotensin-Converting Enzyme Inhibition. Circulation 2006;114:2474–81.10.1161/CIRCULATIONAHA.106.635144Search in Google Scholar PubMed

63. Cao L, Zhu W, Wagar EA, Meng QH. Biomarkers for monitoring chemotherapy-induced cardiotoxicity. Crit Rev Clin Lab Sci 2017;54:87–101.10.1080/10408363.2016.1261270Search in Google Scholar PubMed

64. Gülgün M, Fidancı K, Genç FA, Kesik V. Natriuretic peptide and cardiac troponin levels in doxorubicin-induced cardiotoxicity. Anatol J Cardiol 2016;16:299.10.14744/AnatolJCardiol.2016.7001Search in Google Scholar

65. Cardinale D, Biasillo G, Salvatici M, Sandri MT, Cipolla CM. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn 2017;17:245–56.10.1080/14737159.2017.1283219Search in Google Scholar PubMed

66. Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nisghino Y, Kawada M, et al. High-sensitive troponin T assay can predict anthracycline and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer 2017;24:774–82.10.1007/s12282-017-0778-8Search in Google Scholar PubMed

67. Jones M, O’Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem 2017;54:149–57.10.1177/0004563216650464Search in Google Scholar PubMed

68. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 2018;10(Suppl 35):S4282–95.10.21037/jtd.2018.08.15Search in Google Scholar PubMed PubMed Central

69. Riddell E, Lenihan D. The role of cardiac biomarkers in cardio-oncology. Curr Probl Cancer 2018;42:375–85.10.1016/j.currproblcancer.2018.06.012Search in Google Scholar PubMed

70. Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Del Bello MG, et al. Serial Troponin for early detection of Nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist 2018;23:936–42.10.1634/theoncologist.2017-0452Search in Google Scholar PubMed PubMed Central

71. Simões R, Silva LM, Cruz AL, Fraga VG, de Paula Sabino A, Gomes KB. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: a narrative review. Biomed Pharmacother 2018;107:989–96.10.1016/j.biopha.2018.08.035Search in Google Scholar PubMed

72. Li J, Chang HM, Banchs J, Araujo DM, Hassan SA, Wagar EA, et al. Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin. Cardio-Oncology 2020;6:1.10.1186/s40959-019-0056-3Search in Google Scholar PubMed PubMed Central

73. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 2018;94:126–37.10.1016/j.ejca.2018.02.005Search in Google Scholar

74. Braunwald E. The war against heart failure: the Lancet lecture. Lancet 2015;385:812–24.10.1016/S0140-6736(14)61889-4Search in Google Scholar

75. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020;22:350–61.10.1002/ejhf.1631Search in Google Scholar PubMed

76. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906–13.10.1016/j.jacc.2012.12.048Search in Google Scholar PubMed

77. Vilela EM, Bastos JC, Rodrigures RP, Nunes JP. High-sensitivity troponin after running a systematic review. Neth J Med 2014;72:5–9.Search in Google Scholar

78. Skadberg Ø, Kleiven Ø, Bjørkavoll-Bergseth M, Meilberg T, Bergseth R, Selvåg J, et al. Highly increased Troponin I levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: the North Sea Race Endurance Exercise Study (NEEDED) 2013. Eur J Prev Cardiol 2017;24:885–94.10.1177/2047487317693130Search in Google Scholar PubMed

79. Aengevaeren VL, Hopman MT, Thompson PD, Bakker EA, George KP, Thijssen DH, et al. Exercise-induced cardiac Troponin I increase and incident mortality and cardiovascular events. Circulation 2019;140:804–14.10.1161/CIRCULATIONAHA.119.041627Search in Google Scholar PubMed

80. Skadberg O, Kleiven O, Orn S, Bjørkavoll-Bergseth MF, Melberg TH, Omland T, et al. The cardiac troponin response following physical exercise in relation to biomarker criteria for acute myocardial infarction; the North Sea Race Endurance Exercise study (NEDEED) 2013. Clin Chim Acta 2018;479:155–9.10.1016/j.cca.2018.01.033Search in Google Scholar PubMed

81. Franzini M, Lorenzoni V, Masotti S, Prontera C, Chiappino D, Della Latta D, et al. The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: a multicenter study in Italy. Clin Chim Acta 2015;438:376–81.10.1016/j.cca.2014.09.010Search in Google Scholar PubMed

82. Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta 2015;443:17–24.10.1016/j.cca.2014.06.003Search in Google Scholar PubMed

83. Passino C, Barison A, Vergaro G, Gabutti A, Borrelli C, Emdin M, et al. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta 2015;443:29–38.10.1016/j.cca.2014.09.006Search in Google Scholar PubMed

84. Braunwald E. Biomarkers in heart failure. New Engl J Med 2008;358:2148–59.10.1056/NEJMra0800239Search in Google Scholar PubMed

85. Emdin M, Vittorini S, Passino C, Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009;11:331–5.10.1093/eurjhf/hfp035Search in Google Scholar PubMed

86. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240–319.10.1161/CIR.0b013e31829e8776Search in Google Scholar PubMed

87. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017;70:735–803.10.1161/CIR.0000000000000509Search in Google Scholar PubMed

88. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.10.1093/eurheartj/ehw128Search in Google Scholar PubMed

Article note

Expert Consensus Document from the Study Group on Cardiac Biomarkers of the Italian Scientific Societies of Laboratory Medicine SIBioC (Società Italiana di Biochimica Clinica) and ELAS (Italian Society of the European Ligand Assay Society), and Italian Scientific Society of Cardiology ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri).

Received: 2020-03-22
Accepted: 2020-04-20
Published Online: 2020-05-22
Published in Print: 2021-02-23

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Complex analytical procedures in diagnostic laboratories and the IVDR
  4. Review
  5. Re-examining ferritin-bound iron: current and developing clinical tools
  6. Opinion Papers
  7. Designing a diagnostic Total Testing Process as a base for supporting diagnostic stewardship
  8. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications
  9. EFLM Papers
  10. The Academy of the European Federation of Clinical Chemistry and Laboratory Medicine and the European Register of Specialists in Laboratory Medicine: guide to the Academy and the Register, version 4 – 2020
  11. A proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
  12. Guidelines and Recommendations
  13. High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy
  14. General Clinical Chemistry and Laboratory Medicine
  15. Measurement of serum 17-hydroxyprogesterone using isotope dilution liquid chromatography-tandem mass spectrometry candidate reference method and evaluation of the performance for three routine methods
  16. Evaluation of carbohydrate-deficient transferrin measurements on the V8 capillary electrophoresis system and comparison with the IFCC approved HPLC reference method and N-Latex immunonephelometric assay
  17. The clinical relevance of anti-dsDNA antibodies determined by the Elia™ dsDNA assay in patients with negative indirect immunofluorescence on the HEp-2 cell
  18. A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases
  19. Individual uromodulin serum concentration is independent of glomerular filtration rate in healthy kidney donors
  20. Comparison of iohexol plasma clearance formulas vs. inulin urinary clearance for measuring glomerular filtration rate
  21. Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients
  22. Cardiovascular Diseases
  23. Evaluating the performance of an updated high-sensitivity troponin T assay with increased tolerance to biotin
  24. Infectious Diseases
  25. The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19)
  26. Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay
  27. Comparison of the reliability of Gram-negative and Gram-positive flags of the Sysmex UF-5000 with manual Gram stain and urine culture results
  28. Evaluation of a turbidimetric C-reactive protein assay to monitor early-onset neonatal sepsis in South Kivu (Democratic Republic of the Congo)
  29. Corrigendum
  30. Corrigendum to: Procalcitonin (PCT)-guided antibiotic stewardship in Asia-Pacific countries: adaptation based on an expert consensus meeting
  31. Letters to the Editor
  32. Decision-making based on sFlt-1/PlGF ratios: are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia?
  33. Inter-center agreement in the interpretation of oligoclonal bands
  34. A new founder BRCA1 haplotype identified in the Puglia region is associated with a specific age-related cancer onset in three unrelated families
  35. Predictive values of D-dimer for adverse pregnancy outcomes: a retrospective study
  36. A very uncommon haemoglobin value resulting from a severe acute malnutrition in a 16-month-old child in Ethiopia
  37. Ionized calcium measurements during continuous renal replacement therapy with regional citrate anticoagulation
  38. The hairy cell leukaemia oxymoron: monocytotic monocytopenia
  39. Perchlorate interference with electrolyte analysis
  40. False decrease in serum triglyceride and cholesterol due to massive ascorbate in a bowel preparation solution
https://doi.org/10.1515/cclm-2020-0362
Keywords for this article
cardiac troponin; cardio-toxicity; chemotherapy; high-sensitivity methods; myocardial injury

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Complex analytical procedures in diagnostic laboratories and the IVDR
  4. Review
  5. Re-examining ferritin-bound iron: current and developing clinical tools
  6. Opinion Papers
  7. Designing a diagnostic Total Testing Process as a base for supporting diagnostic stewardship
  8. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications
  9. EFLM Papers
  10. The Academy of the European Federation of Clinical Chemistry and Laboratory Medicine and the European Register of Specialists in Laboratory Medicine: guide to the Academy and the Register, version 4 – 2020
  11. A proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
  12. Guidelines and Recommendations
  13. High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy
  14. General Clinical Chemistry and Laboratory Medicine
  15. Measurement of serum 17-hydroxyprogesterone using isotope dilution liquid chromatography-tandem mass spectrometry candidate reference method and evaluation of the performance for three routine methods
  16. Evaluation of carbohydrate-deficient transferrin measurements on the V8 capillary electrophoresis system and comparison with the IFCC approved HPLC reference method and N-Latex immunonephelometric assay
  17. The clinical relevance of anti-dsDNA antibodies determined by the Elia™ dsDNA assay in patients with negative indirect immunofluorescence on the HEp-2 cell
  18. A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases
  19. Individual uromodulin serum concentration is independent of glomerular filtration rate in healthy kidney donors
  20. Comparison of iohexol plasma clearance formulas vs. inulin urinary clearance for measuring glomerular filtration rate
  21. Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients
  22. Cardiovascular Diseases
  23. Evaluating the performance of an updated high-sensitivity troponin T assay with increased tolerance to biotin
  24. Infectious Diseases
  25. The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19)
  26. Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay
  27. Comparison of the reliability of Gram-negative and Gram-positive flags of the Sysmex UF-5000 with manual Gram stain and urine culture results
  28. Evaluation of a turbidimetric C-reactive protein assay to monitor early-onset neonatal sepsis in South Kivu (Democratic Republic of the Congo)
  29. Corrigendum
  30. Corrigendum to: Procalcitonin (PCT)-guided antibiotic stewardship in Asia-Pacific countries: adaptation based on an expert consensus meeting
  31. Letters to the Editor
  32. Decision-making based on sFlt-1/PlGF ratios: are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia?
  33. Inter-center agreement in the interpretation of oligoclonal bands
  34. A new founder BRCA1 haplotype identified in the Puglia region is associated with a specific age-related cancer onset in three unrelated families
  35. Predictive values of D-dimer for adverse pregnancy outcomes: a retrospective study
  36. A very uncommon haemoglobin value resulting from a severe acute malnutrition in a 16-month-old child in Ethiopia
  37. Ionized calcium measurements during continuous renal replacement therapy with regional citrate anticoagulation
  38. The hairy cell leukaemia oxymoron: monocytotic monocytopenia
  39. Perchlorate interference with electrolyte analysis
  40. False decrease in serum triglyceride and cholesterol due to massive ascorbate in a bowel preparation solution
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2026 De Gruyter Brill
Downloaded on 29.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2020-0362/html
Scroll to top button